OR WAIT null SECS
The company introduced its new advanced elastomer, the 4040/40 formulation, and a new line extension of its AccelTRA component program, AccelTRA Select, at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.
West Pharmaceutical Services, an injectable drug administration company based in Exton, PA, introduced its new advanced elastomer, the 4040/40 formulation, and a new line extension of its AccelTRA component program, AccelTRA Select, at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.
According to a Nov. 5, 2019 company press release, the 4040/40 formulation is available in two 13-mm and 20-mm LyoTec stopper designs for reliability and high functionality. The new device also includes Westar Select quality and low particulate levels, with a design, drug compatibility, and quality to protect drug stability, drive performance, and reduce fill-finish rejects.
Additionally, the AccelTRA Select comes equipped with AccelTRA 13-mm and 20-mm serums and lyo stoppers in numerous configurations, along with a 1–3-mL uncoated plunger, according to the release. The program also utilizes the Westar Select wash process to provide high-quality options for generic drug manufacturers.
“These new elastomer product offerings reflect West’s deep commitment to innovation based on customer insights. Designed with the customers’ challenges in mind, we aim to simplify their journey with drug packaging and delivery solutions and help bring much-needed injectable medicines to patients more quickly and efficiently,” said Karen Flynn, senior vice-president and chief commercial officer, West, in the press release. “CPhI also marks our first full year offering the Integrated Solutions program, our comprehensive approach to working by our customers’ side to help reduce risk and regulatory complexity. Together with these new product offerings, West supports customers as they navigate the journey from early development to commercialization.”
Source: West Pharmaceutical Services